Group 1: Product Pricing and Market Strategy - The price of the company's Huai Mi series products decreased by over 15% year-on-year, while the price of the Zhi Shi series products increased by over 35% year-on-year [4] - Future price trends will depend on raw material harvests and market competition; prices will decrease with abundant raw materials and increase with shortages [4] - The company aims to optimize product structure and reduce costs through new projects to mitigate price volatility risks [4] Group 2: Competitive Landscape - The plant extraction industry is highly segmented, with core products including natural pigments, plant essential oils, and active pharmaceutical ingredients [5] - Barriers to entry for competitors include overcoming technical extraction challenges and obtaining market access certifications [5] Group 3: Market Demand and Growth Potential - The global antioxidant market is projected to grow at a CAGR of 7.2% from 2023 to 2030, with plant extracts accounting for over 40% of the market [6] - The functional food market in China is expected to exceed 1.5 trillion yuan by 2025, driven by rising health demands and consumer spending [7] - The company's vitamin P products are anticipated to see sustained demand growth due to these market trends [7] Group 4: Core Technology and Production Capabilities - Key technological barriers in production include efficient extraction processes, stable large-scale production, and in-depth R&D capabilities [8] - The company has over ten years of experience in high-purity extraction, achieving over 99.5% purity for its quercetin products [8] - Continuous production techniques have improved extraction efficiency by over three times compared to traditional methods [8] Group 5: Strategic Development Plans - The company's development strategy involves three steps: deep processing of vitamin P raw materials, R&D of consumer-end products, and establishing a technical application center [9][11] - The strategy also includes dual market expansion in domestic and international markets, focusing on both pharmaceutical and food sectors [9][11] - The company plans to maintain growth by leveraging technological innovation and expanding into emerging markets like Southeast Asia [12]

北京德恒（重庆）律师事务所 北京德恒（重庆）律师事务所 关于成都欧康医药股份有限公司 2024 年年度股东会的法律意见 北京德恒（重庆）律师事务所 关于成都欧康医药股份有限公司 关于成都欧康医药股份有限公司 2024 年年度股东会的 法律意见 2024 年年度股东会的 法律意见 德恒 15G20250012-01 号 致：成都欧康医药股份有限公司 北京德恒（重庆）律师事务所接受成都欧康医药股份有限公司（以下简称"公 司"）的委托，指派赵禹吉律师、张瑞雪律师（以下简称"本所律师"）出席公 司 2024 年年度股东会（以下简称"本次股东会"），并对本次股东会的合法性进 行见证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）等有关法律、法规、规范性 文件及《成都欧康医药股份有限公司章程》（以下简称"《公司章程》"）的相 关规定而出具。 为出具本法律意见，本所律师审查了公司本次股东会的有关文件资料。本所 律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见所必需 的材料，所提供的原始材料、副本、复印件等材料、口头证言均 ...

证券代码：833230 证券简称：欧康医药 公告编号：2025-047 成都欧康医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 16 日 2.会议召开地点：四川省邛崃市临邛工业园区创业路 15 号公司 B 区技术中 心办公楼三楼第二会议室 3.会议召开方式：现场投票与网络投票相结合 4.会议召集人：公司董事会 5.会议主持人：董事长赵卓君 6.召开情况合法合规的说明： （二）会议出席情况 出席和授权出席本次股东会的股东共 11 人，持有表决权的股份总数 56,460,492 股，占公司有表决权股份总数的 73.0716%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、监事、高级管理人员出席或列席股东会情况 1.公司在任董事 8 人，出席 8 人； 2.公司在任监事 3 人，出席 3 人； ...

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted on May 15, 2025, at Chengdu Oukang Pharmaceutical Co., Ltd. [3] - Attendees included representatives from Kaiyuan Securities, Huayuan Securities, Zhongrui Huyin, and Luxin Chuangtou [3] - Company representatives included Chairman Zhao Zhuojun and CFO Cao Yongqiang [3] Group 2: Impact of Industry Trends - The overall price decline in the vitamin industry has limited impact on the company's product pricing, which is primarily influenced by raw material supply and market demand [5] - The company specializes in flavonoid products, a niche within the vitamin sector, using raw materials like bitter orange and sophora flower [5] Group 3: Production Capacity and Utilization - The new plant's production lines for bitter orange are expected to achieve over 50% capacity utilization by the end of 2025 [6] - The production lines for sophora flower are also projected to reach 50% capacity utilization by year-end 2025, with a focus on fine management and market expansion [6] Group 4: Market Expansion and Partnerships - The company has established strong partnerships in Japan for its sophora flower and bitter orange products, focusing on the food additive and health product markets [7] - Ongoing efforts are being made to deepen cooperation with clients and expand market influence in Japan [7] Group 5: Facility Upgrades and Compliance - Upgrades to the Diosmin and Rutin production lines have been completed, meeting both domestic and international GMP standards [8] - The upgraded lines have passed domestic GMP compliance checks and are in the process of obtaining EuGMP certification [8] Group 6: Financial Projections - The company anticipates a 160% increase in depreciation expenses for 2025 compared to 2024 due to the completion of investment projects [9] - Strategies will be implemented to enhance sales revenue to offset increased depreciation costs [9] Group 7: Profitability and Market Trends - The company's gross margin has declined due to production challenges and increased costs in Q1 2025, but is expected to recover as production lines stabilize [11] - The market for quercetin is projected to grow significantly due to rising health awareness and demand for natural ingredients, particularly in health supplements and functional foods [12]

Market Overview - On May 7, the Shanghai Composite Index rose by 0.80%, with the total margin trading balance reaching 1,808.746 billion yuan, an increase of 7.402 billion yuan from the previous trading day [1] - The margin trading balance in the Shanghai market was 919.064 billion yuan, up by 3.047 billion yuan; in the Shenzhen market, it was 884.493 billion yuan, up by 4.291 billion yuan; and in the Beijing Stock Exchange, it was 5.189 billion yuan, up by 0.065 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 16 sectors saw an increase in margin trading balances, with the non-bank financial sector leading with an increase of 1.761 billion yuan, followed by the computer and defense industries with increases of 1.507 billion yuan and 1.263 billion yuan, respectively [1] Stock Performance - A total of 1,896 stocks experienced an increase in margin trading balances, accounting for 51.66% of the total, with 363 stocks seeing an increase of over 5% [1] - The stock with the largest increase in margin trading balance was Zhongheng Electric, which had a latest balance of 100.3126 million yuan, reflecting an increase of 87.28% from the previous trading day, and its stock price rose by 1.69% [1] - Other notable stocks with significant increases in margin trading balances included Rishidongfang and Huiwei Intelligent, with increases of 69.89% and 58.51%, respectively [1] Top Gainers and Losers - Among the top 20 stocks with the largest increases in margin trading balances, the average increase in stock prices was 5.42%, with notable gainers including Tongyi Aerospace, Daye Co., and Huiwei Intelligent, which saw increases of 25.11%, 20.01%, and 14.01%, respectively [2] - Conversely, the stocks with the largest declines included Chunguang Intelligent, Aima Technology, and Daimai Co., with declines of 5.59%, 3.87%, and 2.93%, respectively [2] Margin Trading Balance Declines - In contrast to the stocks with increased margin trading balances, 1,774 stocks saw a decrease, with 226 stocks experiencing declines of over 5% [4] - The stock with the largest decline in margin trading balance was Xiexin Nengke, with a latest balance of 45.24795 million yuan, reflecting a decrease of 37.65% from the previous trading day [5] - Other stocks with significant declines included Oukang Pharmaceutical and Hengxing Technology, with decreases of 29.99% and 27.74%, respectively [5]

Group 1: Investor Relations Activities - The company held a performance briefing for the 2024 annual report on April 29, 2025, via online communication [4] - Participants included the chairman, general manager, board secretary, financial officer, and sponsor representative [4] Group 2: Market Expansion and Product Certification - The company has obtained the EU export certification for its products, which requires compliance with the European Pharmacopoeia (CEP) and on-site inspections [5] - The company aims to enhance its competitiveness in the EU market by improving production quality and collaborating with EU clients [5] Group 3: Revenue Composition and Market Share - The company's revenue is primarily derived from pharmaceutical raw materials, food additives, cosmetics, and health products [6] - The European market accounts for approximately 40% of exports, while the US, Japan, Australia, and Canada account for about 60% [6] - The NHDC product has captured over 27% of the company's main business revenue in the domestic food additive market [6] Group 4: Growth Drivers and Strategic Focus - Future growth in the plant extract industry is driven by increasing consumer health awareness and advancements in extraction technology [8] - The company plans to deepen its focus on both domestic and international markets, particularly in food additives and pharmaceutical raw materials [9] Group 5: Financial Performance and Profit Margins - The company's revenue increased by 27.78% year-on-year in 2024, attributed to the successful implementation of its strategic plan [7] - The overall gross margin for products increased in 2024, but is expected to decline in 2025 due to rising costs and market competition [10] Group 6: Production and R&D Updates - The company is currently optimizing production processes and has completed 11 R&D projects in 2024 [15] - The new production lines are expected to be fully operational by mid-2025, which will enhance production capacity [14] Group 7: Market Trends and Future Outlook - The company anticipates a gradual recovery in gross margins as production lines stabilize and international trade conditions improve [12][13] - The market for Vitamin P products is expected to grow significantly due to rising health consciousness and expanding application areas [17]

证券代码：833230 证券简称：欧康医药 公告编号：2025-043 成都欧康医药股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 4.发出董事会会议通知的时间和方式：2025 年 4 月 22 日以书面方式发出 5.会议主持人：董事长赵卓君 6.会议列席人员：全体监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规 章等规范性文件，符合《公司法》、《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 独立董事胥兴军、张霜、赵宇霆因工作原因以通讯方式参与表决。 董事伍丽因工作原因以通讯方式参与表决。 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场结合通讯方式 二、议案审议情况 （一）审议通过《关于审议<2025 ...

证券代码：833230 证券简称：欧康医药 公告编号：2025-044 成都欧康医药股份有限公司 第四届监事会第七次会议决议公告 一、会议召开和出席情况 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：公司 B 区技术中心办公楼三楼第二会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2025 年 4 月 22 日以书面方式发出 5.会议主持人：监事会主席顾兵 6.召开情况合法、合规、合章程性说明： 等情况进行全面梳理与审核，编制完成《2025 年一季度报告》。 具体内容详见公司于 2025 年 4 月 28 日在北京证券交易所信息披露平台 （www.bse.cn）披露的《2025 年一季度报告》（公告编号：2025-042）。 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本次会议的召集、召开和议案审议程序等符合有关法律、行政法规、部门规章 等规范性文件，符合 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 成都欧康医药股份有限公司（以下简称"公司"）近日收到四川省药品监督 管理局出具的《中华人民共和国四川省药品监督管理局出口欧盟原料药证明文件》 （ PEOPLE'S REPUBLIC OF CHINA SICHUAN MEDICAL PRODUCTS ADMINISTRATION Written confirmation for active substances exported to EU，以 下简称"WC 证书"）（文件编号：SC250008）。 公司原料药芦丁经四川省药品监督管理局现场检查，符合中国药品 GMP（药 品生产质量管理规范）的要求，等同于欧盟、世界卫生组织以及 ICH Q7（国际 人用药品注册技术协调会关于原料药的药品生产质量管理规范指南）药品 GMP 要求。 证券代码：833230 证券简称：欧康医药 公告编号：2025-040 成都欧康医药股份有限公司 关于公司获得出口欧盟原料药证明文件的公告 3、出口欧盟的原料药：芦丁 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 成都欧康医药股份有限公司 成都欧康医药股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日在北 京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》（公告编 号：2025-013）及《2024 年年度报告摘要》（公告编号：2025-014），为方便广大 投资者更全面深入了解公司 2024 年度经营业绩的具体情况，加强与投资者的互 动交流，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 4 月 29 日（周二）15:00-16:00。 证券代码：833230 证券简称：欧康医药 公告编号：2025-041 2024 年年度报告业绩说明会预告公告 四、 投资者参加方式 本次说明会采用网络方式召开。 投资者可登陆上海证券报官网中国证券网（https://roadshow.cnstock.com）参 与本次年度业绩说明会。为充分尊重投资者、提升交 ...